Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.22, $0.05 better than the analyst estimate of $0.17. Revenue for the quarter came in at $64.4 million versus the consensus estimate of $67.41 million.

GUIDANCE:

Reaffirmed 2018 revenue guidance of $250-270 million

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.